Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-070 - BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study
09:30 - 09:30 | Presenter: Joo-Hang Kim | Author(s): J. Lee, Sang-We Kim, Jin-Hyoung Kang, Dae Ho Lee, Byoung Chul Cho, N. Shiraishi, V. Strout, Keunchil Park
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.07 - Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
16:50 - 17:00 | Presenter: Byoung Chul Cho | Author(s): R. Obermannová, A. Bearz, D. Kim, S. Orlov, G. Borra, Sang-We Kim, Pieter E. Postmus, S.A. Laurie, Keunchil Park, S.L. Geater, A.C. Bettini, K. Osborne, V.Q. Passos, Z. Chen, Rafal Dziadziuszko
- Abstract
Loading...
-
+
MA 11 - Emerging Diagnostic/Biomarkers in NSCLC
- 11:00 - 12:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:M.I. Abdul Wahid, Martin Reck
-
+
MA 11.09 - Real World Data of Rebiopsy, Mutation Status, and Its Association with Plasma Genotyping after EGFR TKI Failure in NSCLC
12:00 - 12:05 | Presenter: Min Hee Hong | Author(s): B.C. Ahn, Hye Ryun Kim, S.J. Heo, J.H. Kim, I.Y. Bang, R. Kim, H.W. Jung, H.J. Cho, H. Kim, H. Kim, Byoung Chul Cho
- Abstract
Loading...
-
+
MA 12 - Circumventing EGFR Resistance
- 11:00 - 12:30
- 10/17/2017
- Location: F205 + F206 (Annex Hall)
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Wan Ling Tan, Nobuyuki Yamamoto
-
+
MA 12.01 - A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
11:00 - 11:05 | Presenter: Ji Soo Park | Author(s): M.H. Hong, Byoung Chul Cho, Hye Ryun Kim
- Abstract
Loading...
-
+
OA 09 - EGFR TKI Resistance
- 11:00 - 12:30
- 10/17/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:Thanyanan Reungwetwattana, Lecia V Sequist
-
+
OA 09.03 - TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
11:20 - 11:30 | Presenter: Myung-Ju Ahn | Author(s): Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. Tsai, James Chih-Hsin Yang, Helena Yu, L. Horn, K. Lee, V. Haddad, M.M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, Geoffrey R. Oxnard
- Abstract
Loading...
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-005 - ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
09:30 - 09:30 | Presenter: Sang-We Kim | Author(s): Byoung Chul Cho, D. Kim, Keunchil Park, M. Tiseo, M.R. Migliorino, A. Santo, J. Lee, D. Vicente, A. Paredes, E. O'Hanrahan, Helano Carioca Freitas, M. Provencio, Y. Chen, P.K. Cheema, A. Milner, J.R. Rigas, Yi-Long Wu, F. De Marinis
- Abstract
Loading... -
+
P3.01-028 - Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial
09:30 - 09:30 | Presenter: Jee Hung Kim | Author(s): Hye Ryun Kim, Min Hee Hong, I.Y. Bang, R. Kim, H.W. Jung, H.J. Cho, H. Kim, H. Kim, Byoung Chul Cho
- Abstract
Loading... -
+
P3.01-050 - A Real World Treatment Study of Osimertinib: ASTRIS Study Korean Subgroup Analysis
09:30 - 09:30 | Presenter: Byoung Chul Cho | Author(s): D. Kim, Keunchil Park, J. Lee, S.S. Yoo, Jin-Hyoung Kang, Sung Yong Lee, C.H. Kim, S.H. Jang, Young-Chul Kim, H. Yoon, Sang-We Kim
- Abstract
Loading...
-
+
P3.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P3.03-021 - In Vitro Pharmacogenomic Platform with a High-Purity Patient-Derived Cell Model
09:30 - 09:30 | Presenter: Hyun Chang | Author(s): S. Kim, H. Kim, Hye Ryun Kim, Byoung Chul Cho
- Abstract
Loading...
-
+
OA 14 - New Paradigms in Clinical Trials
- 11:00 - 12:30
- 10/18/2017
- Location: Room 311 + 312
- Type: Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Alex Adjei, Eun Kyung Cho
-
+
OA 14.06 - Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
11:55 - 12:05 | Presenter: Myung-Ju Ahn | Author(s): Byoung Chul Cho, S. Siena, Alexander Drilon, F. De Braud, Matthew G Krebs, T. John, C. Karapetis, A.D. Johnson, E. Chow-Maneval, P.S. Multani, Robert C. Doebele
- Abstract
Loading...